Abstract 1132P
Background
Epidermal Growth Factor Receptor (EGFR) is the primary target of current molecular therapies in non-small cell lung cancer (NSCLC). Diverse mutation in EGFR exons were associated with worse response to TKI. This highlights the need to study the prevalence Q787Q mutations in the EGFR gene plus their association with clinicopathological characteristics and survival.
Methods
One-hundred and nine patients with EGFR mutations were included in this study. Next-generation sequencing were used to analyzed mutations in EGFR exons 18 to 21 and TP53.
Results
The Q787Q (+) variant was detected in 36.7% of patients, who had worse performance status (42.9%) and plural effusion (34.5%). The principal co-occurrent mutation was TP53 45.1%. Patients with Q787Q (+) received platinum-based chemotherapy in 66.7%, median progression-free survival (PFS) and overall survival (OS) were significantly shorter (7.0 vs. 9.7 months p= 0.010) and (5.6 vs. 20.5 months p< 0.001), respectively.
Conclusions
The synonymous EGFR Q787Q (+) variant represent a worse prognosis factor to platinum-based chemotherapy in Mexican population of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Benecke.
Funding
Has not received any funding.
Disclosure
M. Arroyo-Hernández: Financial Interests, Personal, Invited Speaker: AstraZeneca, Bristol. All other authors have declared no conflicts of interest.